Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Small lymphocytic lymphoma.

W H Morrison1, R T Hoppe, L M Weiss

  • 1Department of Radiation Oncology, Stanford University, CA.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|May 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial Expression of Concern: Overexpression of miR-26a-2 in human liposarcoma is correlated with poor patient survival.

Oncogenesis·2025
Same author

Microsporidia-Emergent Pathogens in the Global Food Chain (Trends in Parasitology 32, 336-348; April 2, 2016).

Trends in parasitology·2016
Same author

Microsporidia - Emergent Pathogens in the Global Food Chain.

Trends in parasitology·2016
Same author

Development of dual fluorescent stage specific reporter strain of Toxoplasma gondii to follow tachyzoite and bradyzoite development in vitro and in vivo.

Microbes and infection·2015
Same author

Parasitic diseases of the heart I: Acute and chronic Chagas' disease.

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology·2015
Same author

Parasitic diseases of the heart II: Toxoplasmosis and other protozoan and helminthic diseases.

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology·2015
Same journal

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Metabolic Modulation in Cancer Care: The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
See all related articles

Small lymphocytic lymphoma (SLL) survival is impacted by B symptoms and nodal architecture. Early-stage SLL patients treated with irradiation show prolonged freedom from relapse and potential cure.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Medicine

Background:

  • Small lymphocytic lymphoma (SLL) is a low-grade non-Hodgkin lymphoma.
  • Understanding prognostic factors and optimal treatment strategies is crucial for patient outcomes.

Purpose of the Study:

  • To review the clinical course and survival of patients with SLL.
  • To identify clinicopathologic factors predicting survival.
  • To evaluate the impact of treatment on relapse and survival.

Main Methods:

  • Retrospective review of 54 patients with SLL.
  • Analysis of clinicopathologic features, including Ann Arbor stage, B symptoms, nodal architecture, and bone marrow involvement.
  • Evaluation of treatment modalities (radiation, chemotherapy, or no initial therapy) and their impact on freedom from relapse (FFR) and survival.

Related Experiment Videos

Main Results:

  • Five- and 10-year survival rates were 76% and 49%, respectively.
  • Absence of B symptoms and pseudofollicular nodal architecture were associated with significantly longer survival.
  • Early-stage (I-II) SLL patients treated with irradiation had 10-year FFR of 80%, while advanced-stage (III-IV) patients had 11% FFR.

Conclusions:

  • B symptoms and diffuse nodal architecture are adverse prognostic factors in SLL.
  • Irradiation is recommended for stage I-II SLL to achieve prolonged FFR and potential cure.
  • Treatment decisions for advanced SLL should consider the lack of significant survival difference between treated and untreated patients.